NRIX — Nurix Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.73bn
- $1.68bn
- $83.98m
Nurix Therapeutics climbs after blood cancer drug trial data
Brief: Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition
Brief: Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity
Brief: Nurix Therapeutics Reports Third Quarter 2025 Financial Results And Provides A Corporate Update
Nurix Therapeutics falls after Q3 results miss
Nurix Therapeutics' Q3 revenue falls 37%, net loss widens
Nurix Therapeutics Inc reports results for the quarter ended May 31 - Earnings Summary
Brief: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sanofi Exercises License Extension Option To Nurix’S Stat6 Program
Brief: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479
Nurix Therapeutics Inc reports results for the quarter ended February 28 - Earnings Summary
Brief: Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune Diseases
Brief: Nurix Therapeutics Announces Multiple Presentations At The American Association For Cancer Research (AACR) 2025 Annual Meeting
Nurix Therapeutics gets 'market perform' rating as Leerink starts coverage
Brief: Nurix Therapeutics Receives U.S. FDA Fast Track Designation For Nx-5948
Brief: Nurix Therapeutics Presents New Positive Data From Phase 1A/1B Clinical Trial Of NX-5948